Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for ≥24 weeks in Europe
ConclusionsEnzalutamide showed antitumour activity in some patients with mCRPC who had previously progressed following ≥24 wk of abiraterone acetate plus prednisone treatment.Patient summaryPatients with mCRPC who progressed on previous abiraterone acetate plus prednisone treatment, with or without prior chemotherapy, received enzalutamide. Although cross-resistance between the two agents was observed in a majority of patients, some still benefited from enzalutamide treatment.
Source: European Urology - Category: Urology & Nephrology Source Type: research
More News: Abiraterone Acetate | Back Pain | Cancer | Cancer & Oncology | Chemotherapy | Pain | Prednisone | Prostate Cancer | Radiography | Statistics | Study | Urology & Nephrology